(GPAT) GP-Act III Acquisition - Ratings and Ratios

Exchange: NASDAQ • Country: United States • Currency: USD • Type: Common Stock • ISIN: (N/A)

Merger, Acquisition, Financial, Services, Shares

GPAT EPS (Earnings per Share)

EPS (Earnings per Share) of GPAT over the last years for every Quarter: "2020-12": -0, "2021-03": -0, "2022-12": -0, "2023-03": -0, "2023-06": -0, "2023-09": -0, "2023-12": -0, "2024-03": -0, "2024-06": 0.08, "2024-09": 0.1, "2024-12": 0.09, "2025-03": 0.08,

GPAT Revenue

Revenue of GPAT over the last years for every Quarter: 2020-12: null, 2021-03: null, 2022-12: null, 2023-03: 0, 2023-06: 0, 2023-09: 0, 2023-12: 0, 2024-03: 0, 2024-06: 0, 2024-09: 0, 2024-12: 0, 2025-03: 0,

Description: GPAT GP-Act III Acquisition

GP-Act III Acquisition Corp. is a special purpose acquisition company (SPAC) that aims to merge with or acquire a business through a share exchange, asset acquisition, or similar business combination. The companys primary objective is to identify a suitable target and facilitate a business combination.

From a financial perspective, GPAT has a market capitalization of $379.86 million, indicating a moderate size. The price-to-earnings (P/E) ratio of 33.03 suggests that the stock may be relatively expensive compared to its earnings. The return on equity (RoE) of 5.65% is relatively modest, implying that the companys financial performance is not exceptionally strong. To further evaluate the companys financial health, we can examine additional key performance indicators (KPIs) such as debt-to-equity ratio, current ratio, and operating cash flow margin.

Further analysis reveals that GPAT operates in the Diversified Financial Services industry, which is a broad category. As a SPAC, the companys success is heavily dependent on its ability to identify and execute a successful business combination. To assess the companys potential, we can examine its management teams track record, the industry trends, and the competitive landscape. Key metrics to monitor include the companys cash holdings, warrant coverage, and the terms of its proposed business combination.

To make an informed investment decision, its essential to evaluate GPATs potential for growth, its valuation, and the risks associated with its business model. Additional KPIs to consider include the companys enterprise value-to-EBITDA (EV/EBITDA) ratio, the return on assets (RoA), and the dividend yield (if applicable). By examining these metrics, we can gain a more comprehensive understanding of GPATs investment potential and make a more informed decision.

Additional Sources for GPAT Stock

News: Wall Street Journal | Benzinga | Yahoo Finance
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle

GPAT Stock Overview

Market Cap in USD 380m
Sector Financial Services
Industry Shell Companies
GiC Sub-Industry Diversified Financial Services
IPO / Inception 2024-07-01

GPAT Stock Ratings

Growth Rating 48.2
Fundamental -2.19
Dividend Rating 0.0
Rel. Strength -12.9
Analysts -
Fair Price Momentum 9.97 USD
Fair Price DCF -

GPAT Dividends

Currently no dividends paid

GPAT Growth Ratios

Growth Correlation 3m 72.7%
Growth Correlation 12m 98.7%
Growth Correlation 5y 98.8%
CAGR 5y 5.21%
CAGR/Max DD 5y 7.65
Sharpe Ratio 12m -1.58
Alpha 1.05
Beta 0.012
Volatility 2.85%
Current Volume 220.2k
Average Volume 20d 0.1k
Stop Loss 10.2 (-3.4%)
What is the price of GPAT shares?
As of August 03, 2025, the stock is trading at USD 10.56 with a total of 220,195 shares traded.
Over the past week, the price has changed by -0.33%, over one month by +0.14%, over three months by +1.49% and over the past year by +5.39%.
Is GP-Act III Acquisition a good stock to buy?
Neither. Based on ValueRay´s Fundamental Analyses, GP-Act III Acquisition is currently (August 2025) neither a good nor a bad stock to buy. It has a ValueRay Fundamental Rating of -2.19 and therefor a neutral outlook according to the companies health.
Based on momentum, paid dividends and discounted-cash-flow analyses, the fair value of GPAT is around 9.97 USD . This means that GPAT is currently overvalued and has a potential downside of -5.59%.
Is GPAT a buy, sell or hold?
GP-Act III Acquisition has no consensus analysts rating.
What are the forecasts for GPAT share price target?
According to our own proprietary Forecast Model, GPAT GP-Act III Acquisition will be worth about 10.8 in August 2026. The stock is currently trading at 10.56. This means that the stock has a potential upside of +1.99%.
Issuer Target Up/Down from current
Wallstreet Target Price - -
Analysts Target Price - -
ValueRay Target Price 10.8 2%